I've watched dozens of reverse splits over three decades. Most are death spirals — companies desperately trying to avoid delisting. But there's a pattern I've noticed: the rare few that time their splits right can multiply investor returns by 10x or more.

The secret? It's not about the split itself. It's about what smart money does in the 48-72 hours afterward, when retail investors are confused and institutional algorithms are recalibrating.

I just found a trader who's built his entire system around these exact moments. His weekend approach is brilliant — he studies the splits that happen Friday after close, then positions before Monday's chaos. The numbers are staggering: 23 winners out of his last 28 weekend plays.

This isn't luck. It's pure technical precision applied to one of the market's most predictable patterns.


🔥 TODAY'S TOP 5 MOVERS

🥇 SMCZ (Defiance Daily Target 2X Short SMCI ETF) $56.22 +53.5%
📰 Defiance Daily Target 2X Short SMCI ETF (SMCZ) Trading Halt  |  📈 Vol: 1.2M
🥈 CURV (Torrid Holdings) $1.77 +43.2%
📰 Torrid Holdings Closes 57 Stores in Q2  |  📈 Vol: 8.1M
🥉 PL (Planet Labs PBC) $34.77 +29.6%
📰 Stock Market Today: Futures Drop Ahead Of 'Triple Witching' Session As  |  📈 Vol: 17.2M
4️⃣ CODX (Co-Diagnostics,) $3.44 +29.4%
📰 Co-Diagnostics Announces Reverse Stock Split  |  📈 Vol: 40.8M
5️⃣ MNDR (Mobile-health Network Solutions) $1.18 +24.7%
📰 Mobile-Health Network Solutions Shares Rocket On AI Data Center Acquis  |  📈 Vol: 19.5M

💡 BONUS BREAKDOWN: CODX (Co-Diagnostics,)

CODX pulled the nuclear option yesterday — a brutal 1-for-30 reverse split that crushed shares from $2.65 to what should've been $79.50. Instead, it opened at $3.44 and somehow rallied 29% on massive volume.

Here's what happened: Co-Diagnostics was facing Nasdaq delisting for trading under $1. The reverse split was their Hail Mary to regain compliance. These moves typically signal desperation — management trying to buy time while the business burns.

But CODX's volume tells a different story. Over 40 million shares traded — that's institutional money making moves. Someone with deep pockets clearly thinks this biotech diagnostic company is oversold at these levels. Their joint venture CoSara is presenting tuberculosis and HPV testing tech at a major conference in India, which could explain the sudden interest.

My honest take? This is pure speculation, not investment. Reverse splits destroy long-term shareholders 90% of the time. The math is simple: if they had to consolidate 30 shares into 1 just to stay listed, what does that tell you about the underlying business?

That said, there's short-term money to be made here for traders who understand the post-split dynamics. The algos are confused, retail is panicking, and smart money often swoops in during this chaos. But you need surgical precision on timing — hold too long and you'll get crushed when reality sets in.

Bottom line: Avoid CODX as an investment. If you're going to trade it, keep your position tiny and set tight stops. This is casino money, not retirement funds.

Until tomorrow,
— Randy Cole, Editor, The Money Memo

Weekend splits like CODX create the most profitable 72-hour windows in trading.

See what I found →

Keep Reading